It isn't. It's barely started.
Sponsored Content
Dear Reader,
You already know the story. Everyone does.
The weight-loss drugs took over the headlines, the drugmakers behind them
became two of the most valuable companies on Earth, and most investors figured
the trade was over.
It isn't. It's barely started.
Because a boom this size doesn't stop at two companies. It needs
manufacturers. Ingredient suppliers. Delivery devices. Telehealth platforms
writing the prescriptions. An entire supply chain most investors have never
looked at.
Our research desk mapped that supply chain and found ten publicly traded
companies positioned to benefit as this market grows.
The GLP-1 Gold Rush: 10 Stocks Riding the Weight-Loss Drug Boom names all ten,
with tickers and the thesis for each.
The report is free today.
Claim My Free Copy of the GLP-1 Report
<[link removed]>
By clicking this link you agree to receive emails from us and our affiliates.
You can opt out at any time.Privacy Policy
<[link removed]>.
— Edward Strauss
Editor, Financial Edge Daily
P.S. Everyone knows the two obvious names. The other ten are where the
opportunity still lives. Get the free list now.
This is a PAID ADVERTISEMENT provided to our customers. Although you have been
sent this email, Stocks on the Rise and all of its affiliates do not endorse
this product nor is it responsible for the content of this ad. Furthermore, we
make no guarantee or warranty about what is advertised above. Through this
website/email you are able to link to other websites which are not under the
control of Stocks on the Rise and all of its affiliates. We have no control
over the nature, content and availability of those sites. The inclusion of any
links does not necessarily imply a recommendation or endorse the views
expressed within them.Full disclaimer here
<[link removed]>.
If you no longer wish to receive emails from Stocks on the Rise, click here to
unsubscribe.
<[link removed]>
Stocks on the Rise | Wyatt Investment Research | 65 Railroad St, Richmond, VT
05477
